NCT00465816 - Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 | Biotech Hunter

Enrollment

611

Participants

Timeline

Start Date

April 11, 2007

Primary Completion Date

April 28, 2008

Study Completion Date

April 28, 2008

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Nimenrix (Meningococcal vaccine 134612)

Single dose intramuscular injection

BIOLOGICAL

Twinrix

3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.

Trial Locations (6)

8200

GSK Investigational Site, Aarhus N

SE-371 41

GSK Investigational Site, Karlskrona

SE-581 85

GSK Investigational Site, Linköping

SE-205 02

GSK Investigational Site, Malmo

SE-701 16

GSK Investigational Site, Örebro

SE-901 85

GSK Investigational Site, Umeå